Arrhythmias are due to irregular contractions and disorganized electrical signals within the heart and are a leading cause of death in the United States (US). Ventricular tachycardia and ventricular fibrillation are the most-serious arrhythmias and are associated with 300k annual US deaths. In comparison, atrial fibrillation (AF) impacts 6M Americans, making it the most common arrhythmia. With nearly 750k annual US hospitalizations and 130k annual US deaths, AF is associated with the highest medical costs, which are projected to exceed $50B by 2035. First-line AF therapies rely on pharmaceuticals to prevent blood clots and to restore proper rhythm. When these approaches fail, catheter ablation is an option. For this procedure, electrical currents (or coolants) are directed to the catheter?s tip to ablate those tissues disrupting normal electrical signals. Catheter ablation is an effective and increasingly-used therapy, with more than 500M procedures performed between 2000 and 2013. However, standard methods are complex and expose electrophysiologists to x-rays. Because manually-deflectable catheters rely on complex tension-wire designs that are operated from a meter away, errors accumulate in the transmission of forces and torques. As a result, precise catheter navigation and heart- wall contact are challenging, which can result in injury and AF recurrence (observed in ~50% of those treated). Robotic platforms attempt to address manual ablation catheter deficiencies. Standard robotic systems manipulate traditional manual catheters and place the electrophysiologist outside the x-ray field. However, the technology?s learning curve is high, catheter tip control is unimproved, and systems are expensive. Magnet- based robotic systems improve upon standard robotic systems by using magnetic fields to apply forces and torques directly to magnet-tipped catheters, which simplifies the catheters. The result is a technology that provides improved navigation and better heart-wall contact. However, magnet-based systems are impractically large, very expensive, hard to install, and difficult to use, in addition to requiring a new c-arm and magnetic shielding for the room. For these reasons, broad adoption of all AF robotic solutions has been slow. As opposed to expending energy in fighting the catheter?s restoring force, the proposed technology redesigns the catheter so that better catheter navigation and heart-wall contact are accomplished using a system whose magnetic field and mass are 6X and 40X smaller, respectively, than previously possible. The result is an affordable technology that 1) provides better catheter-tip control and heart-wall contact, 2) offers an open catheter lumen for electrical leads and irrigation, and 3) does not require custom c-arms and room construction. The team reflects commercially-successful magnetics, robotics, and electrophysiology experts. The Phase I effort focuses on proof of concept of the platform.
The aims i nclude 1) building the prototype magnet system, 2) building catheters and advancer, and 3) evaluating the system?s performance in beating heart phantoms. An FDA pre-submission meeting will be conducted in advance of the Phase II proposal.

Public Health Relevance

Arrhythmias represent a major cause of mortality, where ventricular fibrillation and ventricular tachycardia are associated with 300,000 annual deaths in the United States (US) and atrial fibrillation (AF), which affects nearly six million Americans, is associated with 130,000 annual deaths. As stated in the 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement, catheter ablation is an effective treatment option; however, control of the catheter requires considerable skill, can be imprecise, and can result in variable heart-wall contact which, together, increase the likelihood of injury and arrhythmia recurrence. For this Phase I SBIR application, UN&UP (short for ?Unmet Needs and Underserved Populations?) will demonstrate proof of concept of its patent-pending magnet-based electrophysiology robotic platform that provides superior ablative tip control against the heart wall and overcomes historical limitations related to usability, responsiveness, cost- effectiveness, and integrability.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HL147745-01
Application #
9777244
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Lee, Albert
Project Start
2019-05-01
Project End
2021-04-30
Budget Start
2019-05-01
Budget End
2021-04-30
Support Year
1
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Unandup, LLC
Department
Type
DUNS #
080999638
City
Saint Louis
State
MO
Country
United States
Zip Code
63110